How Analysts View Johnson & Johnson in October

On October 18, Johnson & Johnson announced a fourth-quarter cash dividend of $0.90 per share for its common stock. Johnson & Johnson will pay the dividend to its shareholders on record when the market closes on November 27. The company has announced that the dividend will be paid on December 11.

In October, Johnson & Johnson submitted an MAA (Marketing Authorization Application) to the European Medicines Agency for the approval of esketamine nasal spray for the treatment of adults with treatment-resistant depression and Major Depressive Disorder who have not adequately responded to a minimum of two different prior antidepressant therapies.

Johnson & Johnson’s esketamine nasal spray is a glutamate receptor modulator that’s currently under investigation. Johnson & Johnson’s MAA has been supported by five pivotal Phase 3 trials of esketamine. Earlier, Johnson & Johnson submitted an NDA (New Drug Application) to the FDA for the approval of esketamine in the US market for the same indication.

Of the 20 analysts tracking Johnson & Johnson (JNJ) in October, four have given it “strong buy” ratings, while six have given it “buy” ratings. Nine analysts have given it “holds,” and one analyst has given it a “sell.”

On October 22, Johnson & Johnson had a consensus 12-month target price of $146.21, which reflects a ~5.43% potential return on investment over the next 12 months.

In October, of the 18 analysts tracking Pfizer (PFE) ~50% have given it “buys.” Among the 24 analysts tracking Amgen (AMGN). ~46% have given it “buys.” Of the 19 analysts tracking Bristol-Myers Squibb (BMY), ~32% have given it “buys.”

On October 22, Pfizer (PFE), Amgen, and Bristol-Myers Squibb had consensus 12-month target prices of $42.94, $205.15, and $60.59, respectively, reflecting a ~3.22% fall, a ~3.60% rise, and a ~19.08% rise, respectively, over the next 12 months.